Athena Athena

X
[{"orgOrder":0,"company":"Syndesi Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$130.0 million","newsHeadline":"AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Syndesi Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depressive disorder.

            Lead Product(s): SDI-118

            Therapeutic Area: Neurology Product Name: SDI-118

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: AbbVie Inc

            Deal Size: $1,000.0 million Upfront Cash: $130.0 million

            Deal Type: Acquisition March 01, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY